
Global Quantum Computing in Drug Discovery Market Report and Forecast 2024-2032
Description
Global Quantum Computing in Drug Discovery Market Report and Forecast 2024-2032
The global quantum computing in drug discovery market was valued at USD 400 million in 2023. The market is expected to grow at a CAGR of 13% during the period 2024-2032, reaching USD 1200 million by 2032. This growth is driven by the increasing adoption of artificial intelligence in the healthcare domain, advancements in quantum computing technology, rising investment from pharmaceutical companies, and supportive government policies and investments in healthcare research infrastructure.
Global Quantum Computing in Drug Discovery Market- Analysis
Quantum computing in drug discovery leverages quantum mechanics to solve complex molecular and chemical interactions, significantly accelerating the process of identifying and developing new drugs. This technology promises to transform drug discovery by enhancing the accuracy and efficiency of simulations and predictions, potentially reducing the time and cost involved in bringing new drugs to market. The market for quantum computing in drug discovery is growing due to advancements in quantum technology and increasing investments from pharmaceutical and technology companies.
Market Driver
Advancements in Quantum Computing Technology: Continuous innovations in quantum computing technology are a major driver for its application in drug discovery. These advancements enhance the ability to model complex biological systems and chemical reactions with unprecedented precision, speeding up the discovery process and improving the accuracy of drug development.
Increasing Investment from Pharmaceutical Companies: Pharmaceutical companies are increasingly investing in quantum computing to gain a competitive edge in drug discovery. The ability to rapidly identify and validate drug targets, generate leads, and optimize compounds can significantly reduce the time and cost of drug development, driving market growth.
Rising Demand for Efficient Drug Discovery Processes: The growing need for more efficient and cost-effective drug discovery processes is propelling the adoption of quantum computing. This technology enables detailed simulations and accurate predictions, which can streamline various stages of drug development, from target identification to lead optimization.
Market Challenges
High Cost of Quantum Computing Systems: The high cost associated with quantum computing systems can be a significant barrier to widespread adoption. The expense of acquiring and maintaining advanced quantum hardware and software may limit accessibility, particularly for smaller pharmaceutical companies and research institutions.
Technical Complexity and Skill Requirements: Quantum computing technology is highly complex and requires specialized knowledge and skills. The scarcity of professionals trained in quantum computing and its applications in drug discovery can hinder the market’s growth. Efforts to provide education and training in this field are essential.
Regulatory and Ethical Issues: The integration of quantum computing in drug discovery must navigate regulatory and ethical challenges. Ensuring compliance with existing regulations and addressing concerns related to data security and patient safety are crucial for the successful implementation of this technology.
Future Opportunities
Collaborations and Partnerships: Strategic collaborations and partnerships between quantum computing companies and pharmaceutical firms can drive innovation and market growth. Joint efforts can lead to the development of new quantum algorithms and solutions tailored to drug discovery, enhancing the capabilities of both industries.
Expansion into Emerging Markets: Expanding quantum computing applications into emerging markets presents substantial growth opportunities. As healthcare infrastructure and research capabilities improve in these regions, there is significant potential for adopting advanced technologies like quantum computing in drug discovery.
Development of Quantum Software Solutions: The development of specialized quantum software solutions for drug discovery offers significant market potential. Tailored software can enhance the efficiency and accuracy of quantum simulations and predictions, making the technology more accessible and effective for pharmaceutical research.
Global Quantum Computing in Drug Discovery Market Trends
Integration with Artificial Intelligence and Machine Learning: The integration of quantum computing with artificial intelligence (AI) and machine learning (ML) is a growing trend. AI and ML can enhance the capabilities of quantum algorithms, providing more accurate predictions and insights for drug discovery. This combination can significantly accelerate the drug development process.
Increasing Use of Quantum Simulations: The use of quantum simulations to model complex molecular structures and chemical reactions is becoming more prevalent. These simulations provide detailed insights that are not possible with classical computing, improving the accuracy of drug discovery and development processes.
Focus on Personalized Medicine: The trend toward personalized medicine is driving the adoption of quantum computing in drug discovery. Quantum computing can help develop tailored treatments by analyzing individual genetic and molecular profiles, leading to more effective and targeted therapies.
Growth in Quantum Computing Research: There is a significant increase in research focused on quantum computing applications in drug discovery. Academic institutions and research organizations are investing in exploring new quantum algorithms and techniques to solve complex biological problems, driving innovation and market growth.
Quantum Computing in Drug Discovery Market Segmentation
Market Breakup by Offering
Target Identification/ Validation
Hit Generation / Lead Identification
Lead Optimization
Others
The global quantum computing in the drug discovery market is segmented by offering target identification/validation, hit generation/lead identification, lead optimization, and others. Target identification/validation involves using quantum computing to accurately identify and validate biological targets for new drugs. Hit generation/lead identification focuses on finding potential drug candidates from large chemical libraries. Lead optimization uses quantum simulations to refine and improve the properties of drug candidates. These segments address different stages of the drug discovery process, enhancing efficiency and accuracy.
Market Breakup by Therapeutic Area
Cardiovascular Disorders
CNS Disorders
Dermatological Disorders
Endocrine Disorders
Gastrointestinal Disorders
Immunological Disorders
Infectious Diseases
Musculoskeletal Disorders
Oncological Disorders
Respiratory Disorders
Others
The market is segmented by therapeutic area into cardiovascular disorders, CNS disorders, dermatological disorders, endocrine disorders, gastrointestinal disorders, immunological disorders, infectious diseases, musculoskeletal disorders, oncological disorders, respiratory disorders, and others. Each therapeutic area leverages quantum computing to address specific health conditions, improving drug discovery and development outcomes across various medical fields.
Market Breakup by End User
Pharmaceutical Companies
Biopharmaceutical Companies
Research and Academic Institute
Others
The market is segmented by end-user into pharmaceutical companies, biopharmaceutical companies, research and academic institutes, and others. Pharmaceutical and biopharmaceutical companies use quantum computing to enhance their drug discovery pipelines and gain a competitive edge. Research and academic institutes focus on exploring new quantum algorithms and applications in drug discovery, driving innovation and knowledge in the field.
Market Breakup by Region
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe lead the market due to advanced research infrastructure, significant investments, and high adoption rates of quantum technologies. The Asia Pacific region is experiencing rapid growth due to increasing healthcare investments and growing interest in advanced technologies. Latin America the Middle East and Africa present emerging opportunities with improving research capabilities and healthcare infrastructure.
Global Quantum Computing in Drug Discovery Market Competitive Landscape
The global quantum computing in drug discovery market features key players such as IBM Corp., Alphabet Inc., D-Wave Systems Inc., Microsoft Corporation, Rigetti Computing Inc., Quantum Brilliance Pty Ltd, Xanadu Quantum Technologies Inc., Fujitsu Limited, Intel Corporation, Atos SE, and 1QB Information Technologies, Inc. These companies drive market growth through innovations in quantum computing, strategic partnerships, and market expansion efforts. They offer advanced quantum hardware and software solutions tailored for drug discovery, enhancing the efficiency and accuracy of research processes. Continuous research and development, coupled with collaborations between quantum computing and pharmaceutical companies, strengthen their market presence and drive innovation in the field.
Key Questions Answered in the Report
What was the estimated value of global quantum computing in the drug discovery market in 2023?
What is the expected CAGR of quantum computing in the drug discovery market from 2024 to 2032?
What factors are driving the growth of quantum computing in the drug discovery market?
What challenges does quantum computing in the drug discovery market face?
How do advancements in quantum computing technology impact drug discovery?
What opportunities exist for quantum computing in the drug discovery market in emerging regions?
How is the market segmented by offering quantum computing in the drug discovery market?
Which therapeutic areas are most addressed by quantum computing in drug discovery?
What are the primary end users of quantum computing in drug discovery solutions?
How is the market segmented by region in the quantum computing drug discovery market?
Who are some of the major players in the global quantum computing drug discovery market?
How do privacy and ethical concerns affect the adoption of quantum computing in drug discovery?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global quantum computing in drug discovery market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the global quantum computing in drug discovery market.
The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the global quantum computing in the drug discovery industry and its attractiveness.
The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Quantum Computing in Drug Discovery Market Overview
- 3.1 Global Quantum Computing in Drug Discovery Market Historical Value (2017-2023)
- 3.2 Global Quantum Computing in Drug Discovery Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Quantum Computing in Drug Discovery Market Landscape*
- 5.1 Global Quantum Computing in Drug Discovery Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Quantum Computing in Drug Discovery Market: Product Landscape
- 5.2.1 Analysis by Offering
- 5.2.2 Analysis by Therapeutic Area
- 6 Global Quantum Computing in Drug Discovery Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Quantum Computing in Drug Discovery Market Segmentation (2017-2032)
- 7.1 Global Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 7.1.1 Market Overview
- 7.1.2 Target Identification/ Validation
- 7.1.3 Hit Generation / Lead Identification
- 7.1.4 Lead Optimization
- 7.1.5 Others
- 7.2 Global Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 7.2.1 Market Overview
- 7.2.2 Cardiovascular Disorders
- 7.2.3 CNS Disorders
- 7.2.4 Dermatological Disorders
- 7.2.5 Endocrine Disorders
- 7.2.6 Gastrointestinal Disorders
- 7.2.7 Immunological Disorders
- 7.2.8 Infectious Diseases
- 7.2.9 Musculoskeletal Disorders
- 7.2.10 Oncological Disorders
- 7.2.11 Respiratory Disorders
- 7.2.12 Others
- 7.3 Global Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 7.3.1 Market Overview
- 7.3.2 Pharmaceutical Companies
- 7.3.3 Biopharmaceutical Companies
- 7.3.4 Research and Academic Institute
- 7.3.5 Others
- 7.4 Global Quantum Computing in Drug Discovery Market (2017-2032) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Quantum Computing in Drug Discovery Market (2017-2032)
- 8.1 North America Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 8.1.1 Market Overview
- 8.1.2 Target Identification/ Validation
- 8.1.3 Hit Generation / Lead Identification
- 8.1.4 Lead Optimization
- 8.1.5 Others
- 8.2 North America Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 8.2.1 Market Overview
- 8.2.2 Cardiovascular Disorders
- 8.2.3 CNS Disorders
- 8.2.4 Dermatological Disorders
- 8.2.5 Endocrine Disorders
- 8.2.6 Gastrointestinal Disorders
- 8.2.7 Immunological Disorders
- 8.2.8 Infectious Diseases
- 8.2.9 Musculoskeletal Disorders
- 8.2.10 Oncological Disorders
- 8.2.11 Respiratory Disorders
- 8.2.12 Others
- 8.3 North America Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 8.3.1 Market Overview
- 8.3.2 Pharmaceutical Companies
- 8.3.3 Biopharmaceutical Companies
- 8.3.4 Research and Academic Institute
- 8.3.5 Others
- 8.4 North America Quantum Computing in Drug Discovery Market (2017-2032) by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe Quantum Computing in Drug Discovery Market (2017-2032)
- 9.1 Europe Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 9.1.1 Market Overview
- 9.1.2 Target Identification/ Validation
- 9.1.3 Hit Generation / Lead Identification
- 9.1.4 Lead Optimization
- 9.1.5 Others
- 9.2 Europe Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 9.2.1 Market Overview
- 9.2.2 Cardiovascular Disorders
- 9.2.3 CNS Disorders
- 9.2.4 Dermatological Disorders
- 9.2.5 Endocrine Disorders
- 9.2.6 Gastrointestinal Disorders
- 9.2.7 Immunological Disorders
- 9.2.8 Infectious Diseases
- 9.2.9 Musculoskeletal Disorders
- 9.2.10 Oncological Disorders
- 9.2.11 Respiratory Disorders
- 9.2.12 Others
- 9.3 Europe Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 9.3.1 Market Overview
- 9.3.2 Pharmaceutical Companies
- 9.3.3 Biopharmaceutical Companies
- 9.3.4 Research and Academic Institute
- 9.3.5 Others
- 9.4 Europe Quantum Computing in Drug Discovery Market (2017-2032) by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific Quantum Computing in Drug Discovery Market (2017-2032)
- 10.1 Asia Pacific Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 10.1.1 Market Overview
- 10.1.2 Target Identification/ Validation
- 10.1.3 Hit Generation / Lead Identification
- 10.1.4 Lead Optimization
- 10.1.5 Others
- 10.2 Asia Pacific Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 10.2.1 Market Overview
- 10.2.2 Cardiovascular Disorders
- 10.2.3 CNS Disorders
- 10.2.4 Dermatological Disorders
- 10.2.5 Endocrine Disorders
- 10.2.6 Gastrointestinal Disorders
- 10.2.7 Immunological Disorders
- 10.2.8 Infectious Diseases
- 10.2.9 Musculoskeletal Disorders
- 10.2.10 Oncological Disorders
- 10.2.11 Respiratory Disorders
- 10.2.12 Others
- 10.3 Asia Pacific Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 10.3.1 Market Overview
- 10.3.2 Pharmaceutical Companies
- 10.3.3 Biopharmaceutical Companies
- 10.3.4 Research and Academic Institute
- 10.3.5 Others
- 10.4 Asia Pacific Quantum Computing in Drug Discovery Market (2017-2032) by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America Quantum Computing in Drug Discovery Market (2017-2032)
- 11.1 Latin America Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 11.1.1 Market Overview
- 11.1.2 Target Identification/ Validation
- 11.1.3 Hit Generation / Lead Identification
- 11.1.4 Lead Optimization
- 11.1.5 Others
- 11.2 Latin America Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 11.2.1 Market Overview
- 11.2.2 Cardiovascular Disorders
- 11.2.3 CNS Disorders
- 11.2.4 Dermatological Disorders
- 11.2.5 Endocrine Disorders
- 11.2.6 Gastrointestinal Disorders
- 11.2.7 Immunological Disorders
- 11.2.8 Infectious Diseases
- 11.2.9 Musculoskeletal Disorders
- 11.2.10 Oncological Disorders
- 11.2.11 Respiratory Disorders
- 11.2.12 Others
- 11.3 Latin America Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 11.3.1 Market Overview
- 11.3.2 Pharmaceutical Companies
- 11.3.3 Biopharmaceutical Companies
- 11.3.4 Research and Academic Institute
- 11.3.5 Others
- 11.4 Latin America Quantum Computing in Drug Discovery Market (2017-2032) by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 12 Middle East and Africa Quantum Computing in Drug Discovery Market (2017-2032)
- 12.1 Middle East and Africa Quantum Computing in Drug Discovery Market (2017-2032) by Offering
- 12.1.1 Market Overview
- 12.1.2 Target Identification/ Validation
- 12.1.3 Hit Generation / Lead Identification
- 12.1.4 Lead Optimization
- 12.1.5 Others
- 12.2 Middle East and Africa Quantum Computing in Drug Discovery Market (2017-2032) by Therapeutic Area
- 12.2.1 Market Overview
- 12.2.2 Cardiovascular Disorders
- 12.2.3 CNS Disorders
- 12.2.4 Dermatological Disorders
- 12.2.5 Endocrine Disorders
- 12.2.6 Gastrointestinal Disorders
- 12.2.7 Immunological Disorders
- 12.2.8 Infectious Diseases
- 12.2.9 Musculoskeletal Disorders
- 12.2.10 Oncological Disorders
- 12.2.11 Respiratory Disorders
- 12.2.12 Others
- 12.3 Middle East and Africa Quantum Computing in Drug Discovery Market (2017-2032) by End User
- 12.3.1 Market Overview
- 12.3.2 Pharmaceutical Companies
- 12.3.3 Biopharmaceutical Companies
- 12.3.4 Research and Academic Institute
- 12.3.5 Others
- 12.4 Middle East and Africa Quantum Computing in Drug Discovery Market (2017-2032) by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grant Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Product
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.2 IBM Corp .
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Developments
- 17.2.5 Certifications
- 17.3 Alphabet Inc
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Developments
- 17.3.5 Certifications
- 17.4 D-Wave Systems Inc .
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Developments
- 17.4.5 Certifications
- 17.5 Microsoft Corporation
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Developments
- 17.5.5 Certifications
- 17.6 Rigetti Computing Inc .
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Developments
- 17.6.5 Certifications
- 17.7 Quantum Brilliance Pty Ltd
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Developments
- 17.7.5 Certifications
- 17.8 Xanadu Quantum Technologies Inc .
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Developments
- 17.8.5 Certifications
- 17.9 Fujitsu Limited
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Developments
- 17.9.5 Certifications
- 17.10 Intel Corporation
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Developments
- 17.10.5 Certifications
- 17.11 Atos SE
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Company News and Developments
- 17.11.5 Certifications
- 17.12 1QB Information Technologies, Inc .
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Company News and Developments
- 17.12.5 Certifications
- 18 Global Quantum Computing in Drug Discovery Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.